Abstract

Oleanolic acid (OA) is a triterpenoid and a fantastic molecule with many beneficial effects. However, high-doses and long-term use can produce adverse effects. This study aimed to characterize the hepatotoxic potential of OA. Mice were given OA at doses of 100–3,000 µmol/kg (45–1,350 mg/kg), po for 10 days, and the hepatotoxicity was determined by serum biochemistry, histopathology, and toxicity-related gene expression via real-time RT-PCR. Animal body weight loss was evident at OA doses of 1,000 µmol/kg and above. Serum alanine aminotransferase activities were increased in a dose-dependent manner, indicative of hepatotoxicity. Serum total bilirubin concentrations were increased, indicative of cholestasis. OA administration produced dose-dependent pathological lesions to the liver, including inflammation, hepatocellular apoptosis, necrosis, and feathery degeneration indicative of cholestasis. These lesions were evident at OA doses of 500 µmol/kg and above. Real-time RT-PCR revealed that OA produced dose-dependent increases in acute phase proteins (MT-1, Ho-1, Nrf2 and Nqo1), decreases in bile acid synthesis genes (Cyp7a1 and Cyp8b1), and decreases in liver bile acid transporters (Ntcp, Bsep, Oatp1a1, Oatp1b2, and Ostβ). Thus, the clinical use of OA and OA-type triterpenoids should balance the beneficial effects and toxicity potentials.

Highlights

  • Oleanolic acid (OA) is a triterpenoid that exists widely in fruits, vegetables and medicinal herbs [1,2].OA is used as a dietary supplement and an over-the-counter Chinese medicine for the treatment of liver disorders, inflammatory diseases diabetes, and anticancer therapies in combination with other therapeutics [1,2,3,4,5]

  • Dose-Response of Liver Injury Produced by OA

  • OA is often given via injections to examine its beneficial effects [1,2,3,4,5,6]

Read more

Summary

Introduction

OA is used as a dietary supplement and an over-the-counter Chinese medicine for the treatment of liver disorders, inflammatory diseases diabetes, and anticancer therapies in combination with other therapeutics [1,2,3,4,5]. OA and OA-type triterpenoids are emerging molecules with multiple biological effects to develop therapeutic candidates [2,3,4,5,6]. Phase-3 clinical trials of an OA derivative CDDO-Me (bardoxolone methyl) were halted (http://www.news.yahoo.com) due to safety concerns, and CDDO-Me analogues were found to produce liver injury after 3-month administration to rats [11]

Objectives
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call